FindDrugs.org

Noom Weight Loss / GLP-1 Review

Weight Loss / GLP-1 · Reviewed Sep 14, 2026

5.83/10
Noom operator trust6.07/10See the full Noom brand review
No commitmentCash-payInsurance-billed

Our verdict

Noom is one of the most recognized weight-loss brands in the world, and Noom Med adds a GLP-1 telehealth track on top of its psychology-based coaching. It is large, legitimate (BBB-accredited A+), widely used, and pairs genuine behavioral coaching with medication access in 47 states. But the GLP-1 layer is a newer, program-mediated add-on rather than a purpose-built clinic: prescribers and the dispensing pharmacy are not named, no dose-by-dose titration schedule is published, and pricing is layered and confusing. It also carries a documented consumer-protection history - an auto-renewal class-action settlement (amount not established by a record we retrieved) and persistent billing and cancellation complaints - that weighs heavily on its score.

Price

from $99/mo · 2 plans

Visit Noom

We may earn a commission if you sign up through this link. It never affects rankings or scores. Not medical advice.

Key takeaways

  • Large, established, BBB-accredited (A+) brand with a genuine behavioral/psychology coaching layer and strong momentum
  • Layered Noom Med pricing: ~$70/mo coaching + $279/mo compounded plan (billed $837/12 weeks, med included) or ~$99/mo telehealth fee with the branded drug billed separately
  • Documented consumer-protection history: an auto-renewal class-action settlement (amount unestablished) and a BBB warning after thousands of complaints; cancellation complaints persist
  • Disclosed eligibility screening (BMI 27+/30+, contraindication questionnaire, Quest/Labcorp labs) is a relative GLP-1 strength
  • Opaque GLP-1 operations: no named prescribers and no named pharmacy (Noom does describe a clinician-managed titration approach, without a dose-by-dose schedule); available in 47 states (excludes AL, LA, MS)
  • Trustpilot 4.5/5 across 66,647 reviews, offset by durable billing/cancellation criticism on BBB and ConsumerAffairs

What is Noom Weight Loss / GLP-1?

Noom, Inc. is an established U.S. health-and-wellness company best known for a behavioral, psychology-based weight-loss app. Its medication arm, Noom Med, connects members with U.S.-licensed clinicians (physicians and nurse practitioners) who evaluate a health-history intake and order labs before prescribing GLP-1 medication. The medical program is largely asynchronous and program-mediated, and individual prescribers are not disclosed. Noom Med is available in 47 states, excluding Alabama, Louisiana, and Mississippi, and is BBB-accredited with an A+ rating held since October 2021.

Treatment options

Prices as of Sep 14, 2026 — verify current on the brand's site.

Getting started with Noom

  1. Complete Noom's online health assessment
  2. Have a licensed clinician evaluate your health history, current medications, and goals
  3. Complete pre-prescription labs via Quest or Labcorp
  4. Receive a prescription if eligible (compounded or branded GLP-1), shipped or routed for dispensing
  5. Continue with behavioral coaching alongside the medication track

Methodology scorecard

Scored on Sep 14, 2026 under methodology v6

5.83/10

Coverage: Checked against 4 recorded withdrawals. Marking matches the wording each withdrawal was recorded in, so the same claim stated differently is not marked.

Pricing & cancellation

Visit Noom

All-in price

from $99/mo · 2 options

Cost structure
Auto-renewing subscription; post-settlement added affirmative consent + in-account cancel button; complaints persist.
Insurance vs. cash
Insurance-billed option available
Deal structure
Cancellation
'Cancel anytime' advertised, but cancellation is the brand's most complained-about area; compounded plans bill quarterly ($837/12 weeks) with no mid-cycle refund. Noom settled a class action over a difficult cancellation process.
Forced subscription
Required

Pros & cons

Pros

  • Established, widely recognized company with an enormous user base and strong brand momentum
  • Genuine behavioral/psychology coaching layer alongside the medication track
  • Documented eligibility screening: BMI thresholds, contraindication questionnaire, labs via Quest/Labcorp
  • Wide medication menu (compounded + branded) and availability in 47 states
  • BBB-accredited (A+) and a high-volume Trustpilot presence (~4.5, ~66k reviews)

Cons

  • Long, documented consumer-protection history: an auto-renewal/dark-pattern class-action settlement (amount unestablished) and a BBB warning after thousands of complaints
  • Notorious for hidden costs, billing surprises, and difficult cancellation; compounded plan billed quarterly with no mid-cycle refund
  • Layered/confusing pricing - coaching subscription and Noom Med fee are separate, and branded medication cost is on top
  • GLP-1 clinical operations are opaque: no named prescribers or named pharmacy disclosed
  • Quality-under-growth concerns (repetitive content) and a 2025 pivot to compounded microdosing

Safety

Talk to a licensed clinician

Noom Med screens on disclosed eligibility criteria: BMI of 27+ with a weight-related condition or 30+, a contraindication questionnaire covering medullary thyroid cancer, MEN2, and pregnancy or breastfeeding, and pre-prescription labs (such as A1C and kidney function) via Quest or Labcorp. This documented screening plus labs is a relative GLP-1 strength. Weaknesses are on the clinical-transparency side: oversight is largely asynchronous, prescribers are unnamed, and the dispensing pharmacy is undisclosed. Noom does describe a clinician-managed titration approach on its GLP-1Rx page, though it publishes no dose-by-dose schedule. GLP-1 medications carry standard side effects, and treatment decisions should be made with a licensed clinician. Compounded semaglutide is not individually FDA-approved, and a licensed clinician decides whether it is appropriate for a given patient.

Common side effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Injection-site reactions

Who should not take it

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple endocrine neoplasia syndrome type 2 (MEN2)
  • Pregnancy
  • Breastfeeding

The bottom line

Noom Med pairs a genuinely strong behavioral-coaching brand with a GLP-1 medication track and disclosed eligibility screening. Weigh that against layered, confusing pricing, an opaque clinical operation with no named prescribers or pharmacy, and a documented auto-renewal settlement plus ongoing cancellation complaints before enrolling - and set a reminder to manage the subscription closely.

Visit Noom

We may earn a commission if you sign up through this link. It never affects rankings or scores. Not medical advice.

See how Noom ranks among GLP-1 providers

What changed & why

This brand's own history — every re-review and methodology recompute, logged. Rankings change when the evidence or the rules change, never for payment. See the site-wide methodology ledger for version history.

  1. Sep 14, 2026Methodologymethodology v65.845.83

    We changed how this score is calculated, and Weight Management / GLP-1 score moved from 5.84 to 5.83. 1 of the factors behind it moved. How we score.

    1 factor withdrawn — assessed coverage fell 14 → 13. Part of any score movement here reflects evidence we retracted, not a change in the brand.

  2. Aug 11, 2026Claim withdrawn5.775.84

    Weight Management / GLP-1 score moved from 5.76 to 5.84 after we withdrew a claim we could not source to a primary record. 3 of the factors behind it moved.

    1 factor withdrawn — assessed coverage fell 15 → 14. Part of any score movement here reflects evidence we retracted, not a change in the brand.

  3. Jul 24, 2026Re-review7.605.77

    Weight Management / GLP-1 score moved from 7.60 to 5.76 after a fresh review of the evidence. 15 of the factors behind it moved.

    Whether this score rests on more or less evidence than the previous one is not recorded — the earlier score did not store how many factors it assessed.

Frequently asked questions

Is Noom Med legit?

Yes. Noom, Inc. is an established, BBB-accredited (A+) U.S. company, and Noom Med uses U.S.-licensed clinicians who review a health-history intake and order labs before prescribing. Note that the GLP-1 track is a newer add-on to Noom's coaching app, and the company has a documented billing/cancellation history, including a class-action settlement over auto-renewal practices.

How much does Noom Med cost?

It depends on the plan. The compounded semaglutide plan is $149 for the first 21 days, then $279/month billed as $837 per 12 weeks with the medication included. The branded plan is a telehealth fee only - $69 the first month, then about $99/month - with the brand drug (such as Ozempic, Wegovy, or Zepbound) purchased separately. Both sit on top of Noom's core coaching subscription (around $70/month).

Can I cancel Noom easily?

Cancellation is Noom's most complained-about area. It settled a class action over a difficult cancellation process and back-charging, and later added affirmative-consent disclosures and an in-account cancel button, but complaints persist. The compounded plan bills quarterly with no mid-cycle refund, so cancel ahead of your renewal date and monitor your payment method.

Does Noom name its prescribers and pharmacy?

No. Noom discloses that compounded medication comes from an FDA-registered facility, but it does not name individual prescribing clinicians or the specific dispensing pharmacy. It does describe its titration approach — its GLP-1Rx page answers "What is the dosing schedule?" with a clinician-managed step-up — without publishing a dose-by-dose schedule.

Work at Noom?

If something here is wrong or out of date, send us a correction request. We read every one and decide what changes — it does not edit the review or move a score.

Sources & how we researched this

Scored on 13 of 14 factors · 8 sources cited

Brand site

Regulatory

Reviews

Other

What we couldn't verify

  • Noom does not disclose the names of its prescribing clinicians for the GLP-1 track (opacity, scored low - not excluded).
  • The specific compounding/dispensing pharmacy (503A/503B) is not named to consumers (opacity, scored low).
  • Noom describes a clinician-managed titration approach on noom.com/med/glp-1rx/ ("What is the dosing schedule…" — a low starting dose increased over time) but publishes no dose-by-dose schedule. A previous pass recorded this as "no published titration protocol" and scored it as opacity; a live check on 2026-08-25 found the page answers that question, so the recorded non-disclosure was a fact about our reading. The subscore still reflects the earlier reading and has NOT been recomputed here.
  • Exact current core Noom coaching subscription price not re-verified this session (~$70/mo).
  • Whether a compounded microdose plan is billed $79/mo or $537/12wk is reported inconsistently.
  • Withdrawn — Noom's partner pharmacies. Noom's partner pharmacies are WITHDRAWN as a claim: noom.com/med/glp-1rx/ names no pharmacy (fetched 2026-08-10), and the third-party review site asserting the arrangement does not originate it. Noom does disclose on the same page that its compounded semaglutide is "produced in an FDA-registered facility but has not been reviewed by the FDA".
  • Withdrawn — Noom settlement amount (reported variously as $56m and "over $60m"). The Noom settlement amount (reported variously as $56m and "over $60m") is WITHDRAWN as a figure. It rested on a law-firm marketing blog; the settlement order itself was not retrieved. The docket (Nichols v. Noom Inc., 1:20-cv-03677, S.D.N.Y., terminated 2022-07-12) establishes that the case settled, which is the load-bearing fact.
  • Withdrawn — Bot coaches posing as humans. "Bot coaches posing as humans" is WITHDRAWN. It is an affirmative adverse claim about deceptive practice, sourced to a blog post on an unrelated nutrition app's domain, with no primary record. The BBB complaint pattern, cited separately, carries consumer dissatisfaction honestly and on the ReviewSource axis where it belongs.
  • Withdrawn — characterisation of Noom's titration model as a "gap". The characterisation of Noom's titration model as a "gap" is WITHDRAWN: the source was a diagnostics vendor's blog — neither the originator of the fact nor independent of the category — and Noom publishes no titration schedule of its own to check it against.
  • glp1-titration-autonomy: re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) rather than brand opacity. The withdrawn item was a diagnostics vendor's blog opinion about Noom's titration model. Ours to lose, and we checked exactly one Noom page for a titration schedule. Not established.
Last reviewed Sep 14, 2026 · methodology v6View the ledger

Top pick

Noom 5.83/10